Terms of Reference: Commercialisation and Technology Transfer Project Group

A project group is being established drawing from UEB, Council and Audit Committee membership to support and challenge our considerations of the approach to Technology Transfer and Commercialisation in the future. The trigger for this review is the end of the 10 year term of the Fusion Medical IP pipeline in January 2015.

The purpose and duties of the Project Group will be to:

1) Consider a number of specific questions about our approach to commercialisation, still to be defined, anticipated to be along the lines of:
   a) How should we define the purpose of our commercialisation and technology transfer activities in the future?
   b) How should we fund commercialisation and technology transfer and what approach should we take to maximise funding opportunities available?
   c) In the context of our existing Innovation Impact and Knowledge Exchange strategy how should IP commercialisation be executed in the light of the new circumstances?
   d) How should we judge our success?
   e) Does anything need to change to achieve this success? If so how should we approach our consideration and delivery of these changes?
   f) What, if any, further information, expertise or opinion should be gathered?

2) Consider and comment on future arrangements for commercialising IP both prior to and following the end of the with Fusion/IP Group medical arrangements in January 2015

3) Consider information gathered on the Technology Transfer and Commercialisation operations within the University of Sheffield and other Russell Group Universities and provide guidance on how we should approach IP and commercialisation

Project Group Membership:

- Professor Richard Jones Chairman (PVC Research)
- Professor Mike Hounslow (Faculty PVC Engineering)
- Mr Bob Rabone (CFO)
- Professor Richard Ross (Professor of Endocrinology and Founding Director of Asterion Ltd and Diurnal Ltd)
- Mr David Bott (Council Member)
- Mr Geoffrey Stevens (Audit Committee Member)
- Mr David Brister, Executive Chairman of Crysalin (a spin out from the Biophysics Laboratory of Oxford University) and Optimal Medicine (a clinical decision support tools software business) and Non-Executive Director of Green Biologics (a bio-butanol manufacturing and distribution business) and Alumus of the University of Sheffield.
- Mr Tom Hockaday, Managing Director ISIS Innovations Ltd (Oxford University’s commercialisation company)
- Ms Sarah Fulton (Director of Research and Innovation Services)
- Dr Suzanne Bushnell-Watson (Head of Commercialisation & Assistant Director of Research and Innovation Services)
- Dr Sarah Want (Head of Research Partnerships and Engagement & Assistant Director of Research and Innovation Services)
- Mrs Sue Grocutt Secretary (Finance and Commercial)